Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Med-Science. 2022; 11(3): 1197-201


Is intraoperative remifentanil infusion associated with early postoperative hypertension in intracranial tumor surgery?

Ozgur Komurcu, Yavuz Cecen, Mehtap Pehlivanlar, Fatma Ulger, Binnur Sarihasan.




Abstract

Hemodynamic instability may cause serious complications such as intracranial hemorrhage, stroke, and brain edema in the postoperative period in intracranial tumor surgery. This study investigated the relationship between remifentanil infusion used for anesthesia maintenance in intracranial tumor surgery and postoperative early hypertension. Hemodynamic parameters were recorded in the first 24 hours after intracranial tumor surgery in the postoperative intensive care unit. Hypertension rate, causes, and treatment methods of hypertension in our clinic were compared with the literature. The study included 113 patients. In 83 patients (73.4%), hypertension was detected in the first 24-hour period during the intensive care follow-up. The hypertensive attack was controlled with intravenous opioids administered in 69 (83.1%) of 83 patients with hypertension, and with additional intravenous antihypertensive in 14 (16.9%) patients. Analgesia use was higher in hypertensive patients in the first 24 hours postoperatively (83.1% vs. 30%, P

Key words: Remifentanil, intracranial tumor surgery, hypertension






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.